Status:
ACTIVE_NOT_RECRUITING
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Lead Sponsor:
Gilead Sciences
Conditions:
Primary Biliary Cirrhosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Detailed Description
Primary: To evaluate the long-term safety and tolerability of seladelpar Secondary: * To evaluate the long-term efficacy of seladelpar * To evaluate the effect of seladelpar on patient-reported out...
Eligibility Criteria
Inclusion
- Must have given written informed consent (signed and dated)
- Participated in a PBC study with seladelpar
- Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male individuals who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
Exclusion
- Exclusion criteria are only applicable for individuals with a seladelpar interruption greater than 4 weeks prior to Day 1 of this study and for individuals who participated in CB8025-21838 irrespective of seladelpar interruption.
- Treatment-related adverse event (AE) leading to study drug discontinuation in a previous PBC study with seladelpar
- A medical condition, other than PBC, that in the Investigator's opinion would preclude full participation in the study or confound its results (eg, cancer, any active infection)
- AST or ALT above 3 × the upper limit of normal (ULN)
- Total bilirubin above 2 × ULN
- MELD score ≥ 12. For individuals on anticoagulation medication, evaluation of the baseline INR, in concert with any current dose adjustments in anti-coagulant medications, will be taken into account when calculating this score. This will be done in consultation with the medical monitor.
- Evidence of advanced PBC as defined by the Rotterdam criteria: albumin below 1× the lower limit of normal (LLN) AND total bilirubin above 1 × ULN)
- eGFR ≤45 mL/min/1.73 m2 (calculated by MDRD formula)
- Auto-immune hepatitis
- Primary sclerosing cholangitis
- Known history of alpha-1-antitrypsin deficiency
- Known history of chronic viral hepatitis
- For females, pregnancy or breast-feeding
- Use of colchicine, methotrexate, azathioprine, or long-term use of systemic steroids (eg prednisone, prednisolone, budesonide) (\>2 weeks) within 2 months prior to Screening
- Current use of fibrates or use of fibrates within 3 months prior to Screening
- Current use of obeticholic acid or use of obeticholic acid within 3 months prior to Screening
- Use of an experimental or unapproved treatment for PBC within 3 months prior to Screening
- History of malignancy diagnosed or treated, actively or within 2 years, or active evaluation for malignancy; localized treatment of squamous or non-invasive basal cell skin cancers and cervical carcinoma in-situ is allowed if appropriately treated prior to Screening
- Treatment with any other investigational therapy or medical device within 30 days or within 5 half-lives, whatever is longer, prior to Screening
- Any other condition(s) that would compromise the safety of the individual or compromise the quality of the clinical study, as judged by the Investigator
- Immunosuppressant therapies (eg, cyclosporine, tacrolimus, anti-TNF or other immunosuppressive biologics)
- Other medications that effect liver or GI functions such as absorption of medications or the roux-en-y gastric bypass procedure may be prohibited and should be discussed with the medical monitor on a case-by-case basis
- Positive for:
- Hepatitis B, defined as the presence of hepatitis B surface antigen
- Hepatitis C, defined as the presence of hepatitis C virus ribonucleic acid (RNA)
- Human immunodeficiency virus (HIV) antibody
- Active COVID-19 infection during screening
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
December 12 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03301506
Start Date
December 12 2017
End Date
November 1 2028
Last Update
December 23 2025
Active Locations (108)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Diagnostic Center
Little Rock, Arkansas, United States, 72205
2
Stanford University School of Medicine
Palo Alto, California, United States, 94305
3
California Liver Research Institute
Pasadena, California, United States, 91105
4
University of California Davis Medical Center
Sacramento, California, United States, 95817